Launch Update: CNSide® Diagnostic Now Commercially Available in Texas On July 31, 2025, Plus Therapeutics announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, is launching the CNSide® cerebrospinal fluid (CSF) assay platform in Texas starting August...
CNSide at the Forefront of CNS Metastases Innovation in 2025 On July 10, 2025, Plus Therapeutics announced that its subsidiary, CNSide Diagnostics, LLC, will feature two compelling presentations at the 2025 SNO/ASCO CNS Metastases Conference, taking place August...
On June 26, 2025, Plus Therapeutics delivered a comprehensive business update for its subsidiary, CNSide Diagnostics, unveiling its strategy to enter the U.S. market with the CNSide CSF assay platform (Source: ir.plustherapeutics.com). This update marks an important...
Plus Therapeutics positions CNSide for rapid growth by appointing seasoned leadership In a strategic move to strengthen its diagnostics division, Plus Therapeutics recently named Russell Bradley as President & General Manager of CNSide, alongside Dr. Marc Hedrick...